首页|健艾康浓缩丸联合cART使用对HIV感染者肠道及其菌群的影响

健艾康浓缩丸联合cART使用对HIV感染者肠道及其菌群的影响

Effect of Jianaikang concentrated pill combined with cART on the intestinal and intestinal flora of patients with HIV

扫码查看
目的 研究健艾康浓缩丸联合cART对HIV感染者肠道的影响.方法 纳入HIV感染者26例,试验组13例给予健艾康浓缩丸+cART,对照组13例给予健艾康浓缩丸安慰剂+cART,连续治疗48周.收集两组血液和粪便,通过细胞学检查、16SrRNA高通量测序、短链脂肪酸及肠黏膜损伤标志物测定并进行分析.结果 试验组治疗后CD4+CD45RO+(269.77±57.78)表达水平较前(178.46±83.26)升高(P<0.01),CD4+CCR5+(19.08±5.95)较前(10.46±9.98)升高(P<0.05),CD4+CXCR4+(174.77±63.23)较前(244.46±89.38)降低(P<0.05);对照组治疗后 CD4/CD8 细胞比值(0.81±0.37)较前(0.52±0.25)升高(P<0.05),CD4+CD45RO+(313.15±95.04)较前(195.38±77.56)升高(P<0.01).在属水平,试验组绿脓杆菌属(Pseudomonas)、魏斯菌属(Weissella)、小链杆菌属(Catenibacterium)、放线菌属(Actinomyces)比例高于对照组(P<0.05),试验组泰泽雷拉菌属(Tyzzerella 4)比例低于对照组(P<0.05).试验组除乙酸外其余短链脂肪酸水平低于对照组(P>0.05),试验组外周血肠黏膜损伤标志物含量均低于对照组(P>0.05).结论 经48周治疗后两组HIV感染者肠道存在一定差异.相较于仅用cART,联合健艾康浓缩丸对免疫重建起到协同作用,联合治疗能潜在上调益生菌比例,具有降低肠黏膜损伤风险的趋势.
Objective To study the effect of Jianaikang concentrated pill combined with antiretroviral therapy(cART)on the intestinal tract of patients with HIV.Methods A total of 26 patients with HIV were enrolled.13 patients in the test group were administered Jianaikang concentrated pill+cART,and 13 patients in the control group received Jianaikang concentrated pill placebo+cART,and all the patients were treated for 48 weeks.The blood and stool of the two groups were collected and analyzed by cytological examination,16SrRNA high-throughput sequencing,and short-chain fatty acids and intestinal mucosal injury markers.Results In the test group,the post-treatment expression level of CD4+CD45RO+(269.77±57.78)was higher than at pre-treatment(178.46±83.26)(P<0.01).Additionally,the post-treatment expression level of CD4+CCR5+(19.08±5.95)was higher than at pre-treatment(10.46±9.98)(P<0.05).Conversely,the post-treatment CD4+CXCR4+(174.77±63.23)was lower than that at pre-treatment(244.46±89.38)(P<0.05).In the control group,the post-treatment CD4/CD8 ratio(0.81±0.37)was higher than at pre-treatment(0.52±0.25)(P<0.05),and the post-treatment CD4+CD45RO+(313.15±95.04)was higher than at pre-treatment(195.38±77.56)(P<0.01).At the genus level,the proportions of Pseudomonas,Weissella,Catenibacterium,and Actinomyces in the test group were higher than those in the control group(P<0.05),whereas the proportion of Tyzzerella 4 in the test group was lower than that in the control group(P<0.05).The levels of all short-chain fatty acids,except for acetic acid,in the test group were lower than those in the control group(P>0.05),and the levels of all peripheral intestinal mucosal injury markers in the test group were lower than those in the control group(P>0.05).Conclusions After 48 weeks of treatment,the intestinal tract of the two groups of patients with HIV exhibited distinct differences.Compared with cART alone,combined treatment with Jianaikang concentrated pill produced a synergistic effect on immune reconstruction.Combination therapy can potentially increase the proportion of probiotics and showed a trend toward reducing the risk of intestinal mucosal injury.

jianaikang concentrated pillHIVintestinal microbiotashort-chain fatty acidsintestinal mucosal injury markers

杨琴、杨欣怡、彭鑫、刘晶晶、王玉璐、兰燕玲、苗丁山、苏琛

展开 >

成都中医药大学,成都 610075

四川省中医药科学院,成都 610041

健艾康浓缩丸 艾滋病病毒 肠道菌群 短链脂肪酸 肠道黏膜损伤标志物

四川省中医药管理局科学技术研究专项

2023MS224

2024

中国艾滋病性病
中国性病艾滋病防治协会

中国艾滋病性病

CSTPCD北大核心
影响因子:1.292
ISSN:1672-5662
年,卷(期):2024.30(4)
  • 22